Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | MPO | P05164 | 3/20 | 0.47 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14402410 | 0.93 | TAAR1 (0.56) | TAAR1AOC3MPOLIPGTLR8 | |
| SCHEMBL2584935 | 0.91 | LIPG (0.58) | TAAR1AOC3MPOLIPGTLR8 | |
| SCHEMBL7758952 | 0.91 | LIPG (0.58) | TAAR1AOC3MPOLIPGTLR8 | |
| SCHEMBL14402389 | 0.91 | LIPG (0.58) | TAAR1AOC3MPOLIPGTLR8 | |
| SCHEMBL2241863 | 0.91 | LIPG (0.58) | TAAR1AOC3MPOLIPGTLR8 | |
| SCHEMBL19540031 | 0.91 | LIPG (0.58) | TAAR1AOC3MPOLIPGTLR8 | |
| SCHEMBL19540033 | 0.91 | LIPG (0.58) | TAAR1AOC3MPOLIPGTLR8 | |
| Ethyne SCHEMBL27743288 | 0.90 | TAAR1 (0.52) | TAAR1AOC3MPOLIPGTLR8 | |
| SCHEMBL20382473 | 0.89 | HTR2A (0.52) | TAAR1AOC3LIPGSLC6A4CYP3A4 | |
| SCHEMBL30866618 | 0.86 | TAAR1 (0.62) | TAAR1AOC3MPOIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108929210-A | A kind of synthetic method of the fluoro- 2,2- dichloro propionic aldehyde of pesticide intermediate 3,3,3- tri- | 江苏扬农化工集团有限公司 | 2018-12-04 | — | — | CN | claimed |
| US-4160036-A | ADRENERGIC STIMULANTS | ALLEN & HANBURYS LIMITED (GB) | 1979-07-03 | — | — | US | claimed |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3642198-B1 | SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| US-20210395240-A1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-02 | — | — | US | disclosed |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200299246-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020186199-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008049919-A2 | RHO KINASE INHIBITORS | DEVGEN N.V. (BE) | 2008-05-02 | — | — | WO | disclosed |
| CN-1057088-C | Benzimidazole compounds, their use and preparation | NEUROSEARCH AS (DK) | 2000-10-04 | — | — | CN | disclosed |
| CN-1099391-A | Benzimidazole compounds, their use and preparation | NEUROSEARCH AS (JP) | 1995-03-01 | — | — | CN | disclosed |
| CN-1061598-A | Hydrazine class compound or its salt, its preparation method and contain the sterilant of this compounds | ISHIHRA SANGYO KAISHA LTD (JP) | 1992-06-03 | — | — | CN | disclosed |
| CN-86107990-A | Herbicide | — | 1987-07-01 | — | — | CN | disclosed |
| US-4160036-A | ADRENERGIC STIMULANTS | ALLEN & HANBURYS LIMITED (GB) | 1979-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395240-A1 | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, TPH1 | TAAR1 1521/4885AOC3 375/4885MPO 97/4885 |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | TAAR1 4253/4885AOC3 431/4885MPO 360/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | TAAR1 3699/4885AOC3 4229/4885MPO 290/4885 |
| US-20230022157-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS | CFD, CFH, TFPI | TAAR1 4621/4885AOC3 1249/4885MPO 674/4885 |
| US-20200054614-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | TAAR1 4425/4885AOC3 4383/4885MPO 3042/4885 |
| US-10933054-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | TAAR1 4425/4885AOC3 4383/4885MPO 3042/4885 |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | PRSS1, HPN, SPINT2 | TAAR1 4215/4885AOC3 971/4885MPO 409/4885 |
| US-20200299246-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPN1, PTPN2, PTPN18 | TAAR1 1638/4885AOC3 4260/4885MPO 3107/4885 |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | TAAR1 4253/4885AOC3 431/4885MPO 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.